Invest Securities reiterates its 'buy' recommendation and €50 price target on Assystem, believing that, apart from the sale of stakes in Expleo and Framatome, 'there are theoretically few short-term catalysts'.

Cautioning that the significant acceleration in organic growth linked to the nuclear revival should only begin to materialize from 2027/28 onwards, he considers Wednesday evening's publication of 2022 sales "not an event".

On the other hand, management's message of accelerating organic growth in 2023, which will be quantified on March 14, could offer a new catalyst if it is significant", the analyst believes.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.